NCT05908747View on ClinicalTrials.gov

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

surufatinib + gemcitabine + nab-paclitaxel

surufatinib: 250mg, QD po; nab-paclitaxel: 125mg/m2, I.V., D1/8/15, Q4W; gemcitabine: 1000/m2, ivgtt for more than 30min, D1/8/15, Q4W

Trial Locations (1)

300000

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05908747 - Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer | Biotech Hunter | Biotech Hunter